EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of Survival Outcomes Between Chimeric Antigen Receptor T-Cell Therapy Recipients With and Without Central Nervous System Involvement

Kenta Hayashino, Nobuharu Fujii, Satsuki Murakami, Taro Masunari, Isao Yoshida, Risa Hashida, Satoshi Oka, Yuki Fujiwara, Wataru Kitamura, Chihiro Kamoi, Takumi Kondo, Keisuke Seike und 5 weitere

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.08.001 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Kenta Hayashino und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan; Department of Hematology, Oncology and Respiratory Medicine, Dent…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Central Nervous System Neoplasms, Receptors, Chimeric Antigen, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Large B-cell lymphoma (LBCL) with central nervous system (CNS) involvement has a poor prognosis, primarily because of the high risk of relapse. Chimeric antigen receptor (CAR) T-cell therapy is a curative treatment for relapsed and/or refractory (r/r) LBCL. However, available data on the efficacy and safety of CAR T-cell therapy in patients with r/r LBCL with CNS involvement are limited. MATERIALS AND METHODS: This retrospective study included patients with r/r LBCL who underwent CAR T-cell therapy at our institution between 2019 and 2024. The study endpoints were efficacy and safety in patients with and without a history of CNS involvement. RESULTS: In total, 78 patients underwent CAR T-cell therapy during the observation period, and 10 patients had a history of CNS involvement. Three patients had primary CNS lymphoma, and 7 patients had secondary CNS lymphoma. Although the overall response rate and safety profile were similar between the 2 groups, 9 of the 10 patients experienced relapse, and the CNS group exhibited significantly worse progression-free survival (PFS) than the non-CNS group (median progression-free survival (PFS), 2.2 vs. not reached months; P = .0013). All patients with primary CNS lymphoma received tirabrutinib after failure of CAR T-cell therapy and achieved an objective response, without severe complications. In contrast, none of the patients with secondary CNS lymphoma achieved remission. CONCLUSION: CNS involvement was significantly associated with poor prognosis, highlighting the need for further strategies, such as tirabrutinib, to improve outcomes in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveCentral Nervous System NeoplasmsReceptors, Chimeric AntigenLymphoma, Large B-Cell, DiffuseHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultTreatment OutcomePrognosis

Stichwörter der Autor:innen

CAR T-cell therapyImmune effector call-associated neurotoxicityLarge B-cell lymphomaPost CAR T cell therapyTirabrutinib

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan; Department of Hematology, Oncology and Respiratory Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School…
  • Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan; Division of Transfusion and Cell Therapy, Okayama University Hospital, Okayama, Japan.
  • Department of Hematology, Aichi Medical University, Nagakute, Japan.
  • Department of Hematology, Chugoku Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuyama, Japan.
  • Department of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
  • Division of Hematology, Ehime Prefectural Central Hospital, Matsuyama, Japan.

Zitieren

APA

Hayashino, K., Fujii, N., Murakami, S., Masunari, T., Yoshida, I., Hashida, R., Oka, S., Fujiwara, Y., Kitamura, W., Kamoi, C., Kondo, T., Seike, K., Fujiwara, H., Asada, N., Ennishi, D., Fujii, K., & Maeda, Y. (2025). Comparison of Survival Outcomes Between Chimeric Antigen Receptor T-Cell Therapy Recipients With and Without Central Nervous System Involvement. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.08.001

Vancouver

Hayashino K, Fujii N, Murakami S, Masunari T, Yoshida I, Hashida R, et al. Comparison of Survival Outcomes Between Chimeric Antigen Receptor T-Cell Therapy Recipients With and Without Central Nervous System Involvement. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.08.001

BibTeX
@article{Hayashino2025,
  author = {Hayashino, Kenta and Fujii, Nobuharu and Murakami, Satsuki and Masunari, Taro and Yoshida, Isao and Hashida, Risa and Oka, Satoshi and Fujiwara, Yuki and Kitamura, Wataru and Kamoi, Chihiro and Kondo, Takumi and Seike, Keisuke and Fujiwara, Hideaki and Asada, Noboru and Ennishi, Daisuke and Fujii, Keiko and Maeda, Yoshinobu},
  title = {Comparison of Survival Outcomes Between Chimeric Antigen Receptor T-Cell Therapy Recipients With and Without Central Nervous System Involvement},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.08.001}
}
Kostenlos starten →